

Rapport 2018/281

Diagnostik och behandling av epilepsi

Plats	Stod	Ska stå	Korrigeringsdatum
Sid 45	(22 procentenheter)	(24 procentenheter)	2018-12-11
Sid 46	(22 procentenheter)	(24 procentenheter)	2018-12-11
Sid 46	Skillnaden är 0,22	Skillnaden är 0,24	2018-12-11
Sid 46	0,06 till 0,45	0,04 till 0,45	2018-12-11
Sid 47	RD 0,22	RD 0,24	2018-12-11
Sid 47	(0,06 till 0,45)	(0,04 till 0,45)	2018-12-11
Sid 65	RR 1,52	RR 1,53	2018-12-11
Sid 65	(1,28 till 1,81)	(1,27 till 1,86)	2018-12-11
Sid 69	(0,13 till 0,29)	(0,12 till 0,31)	2018-12-11
Sid 73	(0,20 till 0,35)	(0,20 till 0,34)	2018-12-11
Sid 73	Första radens (Andel patienter med \geq anfallsreduktion)	Första radens kommentar flyttad till sista raden (Andel patienter som avbryter studien pga. biverkningar)	2018-12-11
Sid 163	114. Brodie MJ. Erratum: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy (The Lancet (February 25) (476)). Lancet 1995;345:662.	114. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitensky V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31-41.	2018-11-15

Följande studier har fallit bort i referenslistan i rapporten.

Al-Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2013;Cd001415.

Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999;40:1147-54.

Beghi E, Musicco M, Viani F, Bordo B, Hauser WA, Nicolosi A. A randomized trial on the treatment of the first epileptic seizure. Scientific background, rationale, study design and protocol. First Seizure Trial Group (FIR.S.T. Group). Ital J Neurol Sci 1993;14:295-301.

Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.

Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. <i>Epilepsia</i> 2010;51:958-67.
Chung SS, Fakhoury TA, Hogan RE, Nagaraddi VN, Blatt I, Lawson B, et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. <i>Epilepsia</i> 2014;55:1077-87.
Daszkiewicz P, Kowalczyk P, Roszkowski M. Surgical treatment of neuronal-glia tumors of mesial-basal part of temporal lobe: Long term outcome and control of epilepsy in pediatric patients. <i>Neurol Neurochir Pol</i> 2017
French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. <i>Acta Neurol Scand</i> 2014;129:143-53.
Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. <i>Neurology</i> 2006;66:1654-60.
Inoue Y, Yagi K, Ikeda A, Sasagawa M, Ishida S, Suzuki A, et al. Efficacy and tolerability of levetiracetam as adjunctive therapy in Japanese patients with uncontrolled partial-onset seizures. <i>Psychiatry Clin Neurosci</i> 2015;69:640-8.
Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampamil for refractory partial-onset seizures. <i>Neurology</i> 2012;78:1408-15.